[Federal Register Volume 59, Number 230 (Thursday, December 1, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-29593]


[[Page Unknown]]

[Federal Register: December 1, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE
Antitrust Division

 

Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Genzyme Corporation and Celtrix 
Pharmaceuticals, Inc.

    Notice is hereby given that, on September 16, 1994, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Genzyme Corporation and 
Celtrix Pharmaceuticals, Inc. have filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing (1) the identities of the parties and (2) the 
nature and objective of the venture. The notifications were filed for 
the purposes of invoking the Act's provisions limiting the recovery of 
antitrust plaintiffs to actual damages under specified circumstances. 
Pursuant to section 6(b) of the Act, the identities of the parties are 
Genzyme Corporation, Cambridge, MA; and Celtrix Pharmaceuticals, Inc., 
Santa Clara, CA. The general area of planned activity is to develop, 
and subsequently commercialize, Transforming Growth Factor Beta-2 for 
tissue repairs, treatment of multiple sclerosis, and other systemic 
applications.
Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 94-29593 Filed 11-30-94; 8:45 am]
BILLING CODE 4410-01-M